Charité Campus Virchow-Klinikum

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis4 trials
• Childhood cancers2 trials
• Lung cancer2 trials
• Atopic dermatitis (eczema)1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Endometrial cancer1 trial
• Epilepsy1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gastric and oesophageal cancer1 trial
• Glioblastoma1 trial
• and 7 more

Phase

• Phase 313 trials
• Phase 24 trials
• Phase 1/21 trial

Status

• Completed8 trials
• Active, not recruiting6 trials
• Recruiting4 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company9 trials
• Biogen1 trial
• CVRx, Inc.1 trial
• Daiichi Sankyo Inc.1 trial
• GPOH gGmbH1 trial
• and 7 more

Running trials

• Recruiting

  Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma

  2022-500676-59-00· Phase 2· GPOH gGmbH· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

  Contact: Elena Braicu (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Münevver Demir (principal investigator)

• Recruiting

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· Phase 3· Daiichi Sankyo Inc.· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The SELUTION DeNovo Study

  NCT04859985· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

  NCT03958877· Phase 3· Biogen· Source

• Recruiting

  BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

  NCT02880618· CVRx, Inc.· Source

  Contact: Nicole Baumann

• Active, not recruiting

  eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

  NCT02767804· Phase 3· Xcovery Holdings, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Terminated

  A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

  NCT05678257· Phase 2· NuCana plc· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Completed

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Phase 2· Incyte Corporation· Source

• Completed

  A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Phase 1/2· Eli Lilly and Company· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

  NCT03773965· Phase 3· Eli Lilly and Company· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source